Literature DB >> 19404190

Effects of amantadine in children with impaired consciousness caused by acquired brain injury: a pilot study.

Mary A McMahon1, Jilda N Vargus-Adams, Linda J Michaud, Judy Bean.   

Abstract

OBJECTIVE: To conduct a pilot study of amantadine in children with impaired consciousness caused by acquired brain injury, to establish design feasibility, and to assess the effect on level of arousal and consciousness.
DESIGN: Randomized, double-blind, placebo-controlled crossover trial. Seven subjects (mean age, 12.7 yrs) with an acquired brain injury (mean duration, 6 wks) were randomized to receive either 3 wks of placebo or amantadine, followed by a 1-wk washout period and then 3 wks of the other agent. Main outcome measures were the Coma/Near-Coma Scale and Coma Recovery Scale-Revised, each done three times per week. Subjective evaluations of change in arousal and consciousness by the parent and physician were done weekly.
RESULTS: Five subjects completed the study. There was no significant difference in the slopes of recovery during either arm for the Coma/Near-Coma Scale (P = 0.24) or the Coma Recovery Scale-Revised (P = 0.28), although improvements in consciousness were noted by the physician during weeks when amantadine was given (P = 0.02).
CONCLUSIONS: This study suggests that amantadine facilitates recovery of consciousness in pediatric acquired brain injury and provides important information necessary to design future more definitive studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19404190     DOI: 10.1097/PHM.0b013e3181a5ade3

Source DB:  PubMed          Journal:  Am J Phys Med Rehabil        ISSN: 0894-9115            Impact factor:   2.159


  8 in total

1.  Clinical and electroencephalographic on-off effect of amantadine in chronic non-traumatic minimally conscious state.

Authors:  A Estraneo; A Pascarella; P Moretta; V Loreto; L Trojano
Journal:  J Neurol       Date:  2015-05-10       Impact factor: 4.849

Review 2.  Awakenings and awareness recovery in disorders of consciousness: is there a role for drugs?

Authors:  Francesca Pistoia; Elisa Mura; Stefano Govoni; Massimo Fini; Marco Sarà
Journal:  CNS Drugs       Date:  2010-08       Impact factor: 5.749

3.  Evaluation of Outcomes in Patients Receiving Amantadine to Improve Alertness After Traumatic Brain Injury.

Authors:  Rim M Hadgu; Amne Borghol; Christopher Gillard; Candice Wilson; Suzan Elqess Mossa; Megan McKay; Charles Jastram; Ifeanyi O Onor
Journal:  Hosp Pharm       Date:  2020-05-17

4.  Emerging Treatments for Disorders of Consciousness in Paediatric Age.

Authors:  Hassna Irzan; Marco Pozzi; Nino Chikhladze; Serghei Cebanu; Artashes Tadevosyan; Cornelia Calcii; Alexander Tsiskaridze; Andrew Melbourne; Sandra Strazzer; Marc Modat; Erika Molteni
Journal:  Brain Sci       Date:  2022-01-31

5.  A Narrative Review of Pharmacologic and Non-pharmacologic Interventions for Disorders of Consciousness Following Brain Injury in the Pediatric Population.

Authors:  Nathan K Evanson; Andrea L Paulson; Brad G Kurowski
Journal:  Curr Phys Med Rehabil Rep       Date:  2016-02-17

6.  Feasibility of the music therapy assessment tool for awareness in disorders of consciousness (MATADOC) for use with pediatric populations.

Authors:  Wendy L Magee; Claire M Ghetti; Alvin Moyer
Journal:  Front Psychol       Date:  2015-05-27

7.  Prescribing Patterns of Amantadine During Pediatric Inpatient Rehabilitation After Traumatic Brain Injury: A Multicentered Retrospective Review From the Pediatric Brain Injury Consortium.

Authors:  Matthew J McLaughlin; Eric Caliendo; Ryan Lowder; William D Watson; Brad Kurowski; Katherine T Baum; Laura S Blackwell; Christine H Koterba; Kristen R Hoskinson; Sarah J Tlustos; Kanecia O Zimmerman; Sudhin A Shah; Stacy J Suskauer
Journal:  J Head Trauma Rehabil       Date:  2021-07-26       Impact factor: 3.117

Review 8.  Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials.

Authors:  Wojciech Danysz; Andrzej Dekundy; Astrid Scheschonka; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2021-02-23       Impact factor: 3.575

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.